Last reviewed · How we verify
HP518 - Dose Escalation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HP518 - Dose Escalation (HP518 - Dose Escalation) — Hinova Pharmaceuticals Aus Pty Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HP518 - Dose Escalation TARGET | HP518 - Dose Escalation | Hinova Pharmaceuticals Aus Pty Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HP518 - Dose Escalation CI watch — RSS
- HP518 - Dose Escalation CI watch — Atom
- HP518 - Dose Escalation CI watch — JSON
- HP518 - Dose Escalation alone — RSS
Cite this brief
Drug Landscape (2026). HP518 - Dose Escalation — Competitive Intelligence Brief. https://druglandscape.com/ci/hp518-dose-escalation. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing